About


What is Calliope? 

Calliope, the Contraceptive Pipeline Database, houses information on potential contraceptive targets and leads in early development, products in pre-clinical and clinical development, and a selection of products with limited market availability. The focus of the database is on novel and long-acting products under active development. Hormonal oral contraceptives, unless they represent a new technology or active pharmaceutical ingredient, and male condoms are not included.

The entries in the Calliope database can be viewed in two ways:

  1. By phase in the development pipeline, meaning where the product, target, or lead is in its development, organized into three phases: Discovery & Early Development, Pre-Clinical & Clinical Development, and Limited Market Availability; or
  2. By user sex and type (hormonal or nonhormonal) in a table format.

Entries are categorized into development phases and stages:

  • The Discovery & Early Development phase includes known and potential biological targets for which compounds, and eventually products, could be developed. Targets are indicated in the database by a target icon. Early stage leads with known biological targets are included here as well. Where relevant, entries for leads and products are cross-referenced to their respective target(s). Contraceptive leads and products that have not yet entered pre-clinical testing, including those undergoing prototype development, are also included in this phase.

  • The Pre-Clinical & Clinical Development phase includes products that have begun pre-clinical research, through clinical studies and regulatory review.

  • The Limited Market Availability phase comprises a selection of products already marketed in at least one country or with the potential for wider distribution in low and middle-income countries. This includes products that have recent approval from either a stringent regulatory authority (SRA; the U.S. Food & Drug Administration or the European Medicines Agency) and/or the World Health Organization Prequalification program. 

Calliope includes entries that are both in active development and those that are currently inactive; however, the focus is on those under active R&D, and the database is not intended to be exhaustive in the inactive category. This categorization applies mostly to the products in pre-clinical and clinical development.

Read more about how to explore the database entries on the How to Use page.

Audience

This database has been developed to meet the informational needs of contraceptive researchers, program managers, policymakers, and procurers. Calliope is not intended to provide medical advice for patients learning about their contraceptive options (see Disclaimer below). Please tell us who you are by completing our user survey.  

Who We Are 

Calliope, the Contraceptive Pipeline Database, is coordinated by FHI 360 as part of the Contraceptive Technology Innovation (CTI) Exchange, www.ctiexchange.org, under the CTI Initiative with support from the Bill & Melinda Gates Foundation.

Updates 

We strive to update information on Calliope on an annual basis. If you have new entries to suggest for the database, or updates to existing entries, please contact us at calliope@fhi360.org.

Contact Us

For more information about Calliope, the Contraceptive Pipeline Database, or if you would like to add an additional entry to the database, please email us at calliope@fhi360.org.

Disclaimer

The information provided on this website is for educational and research purposes. It is not intended as medical advice for patients learning about their contraceptive options, and it should not be used for purposes of medical diagnosis or treatment, or as a substitute for medical advice from qualified medical professionals.

While we strive to ensure that the information provided through this website is accurate and up-to-date, the information is provided “as is” and we make no representations or warranties of any kind, either express or implied, as to its accuracy, completeness, reliability, timeliness, or effectiveness. Any use of or reliance on the information is strictly at the user’s own risk. We disclaim all liability or responsibility for any loss, damage, injury, or harm arising from the use of or reliance on the information.

Links on this website to external Internet sites are provided as a convenience and for informational purposes only. They do not constitute endorsement or approval by us of any products, services, information, or opinions offered on the external sites, and do not establish or suggest any association between us and the sponsors of those sites. The mention of any specific companies, products, or services on this website does not constitute endorsement or recommendation by us.